Colorectal squamous cell carcinoma (SCC) is an extremely rare primary malignant tumor of the colon and rectum, accounting for <0.5% of all colorectal cancers. Most commonly found in the rectum, particularly at the anorectal junction, and may be difficult to differentiate from anal canal SCC. HPV infection, chronic inflammation (ulcerative colitis, schistosomiasis), and immunosuppression are risk factors. On CT, it appears as asymmetric wall thickening with heterogeneous enhancement and perirectal invasion. On MRI, diffusion restriction is prominent with intermediate-to-high signal on T2-weighted sequences. Treatment response to chemotherapy differs from adenocarcinoma — cisplatin/5-FU based regimens are preferred. Prognosis is generally poor with advanced stage common at diagnosis.
Age Range
45-75
Peak Age
60
Gender
Female predominant
Prevalence
Uncommon
The pathogenesis of colorectal SCC is not fully understood; several hypotheses are proposed. (1) Squamous metaplasia hypothesis: Chronic mucosal damage (ulcerative colitis, schistosomiasis, radiation) causes normal glandular epithelium to undergo squamous metaplasia, and carcinoma develops from this metaplastic focus. (2) Pluripotent stem cell hypothesis: Pluripotent stem cells at colorectal crypt bases have both glandular and squamous differentiation capacity — oncogenic transformation occurs in the squamous differentiation direction. (3) HPV hypothesis: Especially at the anorectal junction, HPV (type 16/18) infection inactivates p53 and Rb tumor suppressor proteins through E6/E7 oncoproteins, initiating squamous cell transformation. Heterogeneous enhancement on CT reflects vascularization differences between necrotic areas and viable tumor tissue. Diffusion restriction on MRI results from dense cellularity and high nuclear/cytoplasmic ratio of squamous cells — tight cell-cell junctions markedly restrict water molecule movement. SCC's cisplatin sensitivity derives from DNA cross-linking mechanisms exploiting DNA repair defects in squamous cells.
Heterogeneously enhancing mass at the anorectal junction with inguinal lymph node enlargement — inguinal drainage pattern seen in SCC unlike colorectal adenocarcinoma. This combination strongly suggests SCC diagnosis.
In portal venous phase, asymmetric, irregular wall thickening with heterogeneously enhancing mass in rectum or colon is observed. Central necrosis areas appear low-density. Perirectal fat infiltration, fascial involvement, and adjacent organ invasion are assessed.
Report Sentence
A [size] mm length asymmetric wall thickening with heterogeneously enhancing mass in the [location] [rectum/colon] is identified, consistent with malignancy.
On DWI, the tumor demonstrates marked diffusion restriction — high signal on b=800-1000 sequences, low signal on ADC map. ADC values are generally <1.0 × 10⁻³ mm²/s. Diffusion restriction clearly delineates tumor boundaries and is used for treatment response assessment.
Report Sentence
On DWI, the tumor demonstrates marked diffusion restriction with low signal on ADC map (ADC: [value] × 10⁻³ mm²/s).
On T2-weighted sequences, the tumor shows intermediate-to-high signal. Obliteration of mesorectal fat planes and relationship with mesorectal fascia are evaluated — critical for staging. Necrotic areas appear more hyperintense on T2.
Report Sentence
On MRI T2-weighted sequence, a mass demonstrating intermediate-to-high signal in the [location] rectum is identified, [involved/uninvolved] with mesorectal fascia.
In arterial/portal venous phase, perirectal, iliac, and inguinal lymph node enlargement is assessed. Inguinal LAP frequency is higher in SCC than adenocarcinoma — particularly in anorectal junction tumors, lymphatic drainage directs to inguinal nodes. Necrotic central low-density LAP suggests metastatic involvement.
Report Sentence
[Perirectal/iliac/inguinal] lymph nodes with largest [size] mm short axis are identified, requiring evaluation for metastatic LAP.
On PET-CT, the primary tumor demonstrates prominent FDG uptake (SUVmax generally >10). Metastatic lymph nodes and distant metastases are also detected as FDG-avid. Metabolic response (SUV change) is a critical parameter in treatment response assessment.
Report Sentence
On PET-CT, the [location] tumor demonstrates prominent FDG uptake (SUVmax: [value]).
On non-contrast CT, rectal or colonic wall thickening with soft tissue density mass is observed. Calcification is rare, necrotic areas may show low density. Local invasion findings are detected as perirectal fat infiltration.
Report Sentence
On non-contrast CT, soft tissue density wall thickening with perirectal fat infiltration is identified in the [location] rectum.
Criteria
Keratin pearls and individual cell keratinization prominent. Well-differentiated type.
Distinct Features
Generally better prognosis. May appear more homogeneous on CT.
Criteria
Keratinization minimal or absent. Less differentiated, more aggressive.
Distinct Features
Worse prognosis. More heterogeneous and necrotic appearance on CT.
Criteria
Rare variant showing basement membrane-like structures and peripheral palisading.
Distinct Features
Stronger HPV association. Better response to chemoradiotherapy. More common at anorectal junction.
Distinguishing Feature
Adenocarcinoma most common colorectal cancer, may contain mucinous component; SCC rare, anorectal junction with inguinal LAP — differentiation by histology
Distinguishing Feature
Lymphoma segmental wall thickening, aneurysmal dilatation; SCC focal mass, perirectal invasion more prominent
Distinguishing Feature
Crohn's transmural inflammation, skip lesions, fistula; SCC focal mass, prominent diffusion restriction
Distinguishing Feature
UC diffuse mucosal involvement, continuous from rectum; SCC focal mass, invasion beyond mucosal-submucosal boundary
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
specialist-referralColorectal SCC diagnosis must be histopathologically confirmed — keratinization, intercellular bridges, p63/CK5/6 positivity are diagnostic. Chemoradiotherapy (cisplatin/5-FU + radiotherapy) is primary treatment — similar to anal canal SCC protocols (Nigro protocol). Surgery is applied in incomplete response or recurrence. HPV typing may affect treatment planning. Prognosis is worse than adenocarcinoma — 5-year survival 30-50%. Prognosis is better in early-stage (T1-T2) cases.
Primary treatment is chemoradiation (Nigro protocol). Surgery is only for residual disease. MRI is the standard modality for staging and treatment response assessment. PET-CT is used for staging and post-treatment evaluation.